Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $446.8 million.

  • Catalyst Pharmaceuticals' Retained Earnings rose 9491.29% to $446.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $446.8 million, marking a year-over-year increase of 9491.29%. This contributed to the annual value of $285.2 million for FY2024, which is 13514.17% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Retained Earnings is $446.8 million, which was up 9491.29% from $394.0 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Retained Earnings peaked at $446.8 million during Q3 2025, and registered a low of -$46.3 million during Q1 2021.
  • For the 5-year period, Catalyst Pharmaceuticals' Retained Earnings averaged around $123.6 million, with its median value being $86.4 million (2023).
  • Its Retained Earnings has fluctuated over the past 5 years, first skyrocketed by 5004.2% in 2021, then surged by 703280.58% in 2023.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Retained Earnings stood at -$26.3 million in 2021, then skyrocketed by 289.52% to $49.9 million in 2022, then soared by 143.22% to $121.3 million in 2023, then surged by 135.14% to $285.2 million in 2024, then skyrocketed by 56.68% to $446.8 million in 2025.
  • Its last three reported values are $446.8 million in Q3 2025, $394.0 million for Q2 2025, and $341.9 million during Q1 2025.